Drugs · Entity Annotation Prototype (beta)

8articles mentioning drugs

36drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: DTG ×

DTG

This drug is selected. Its supporting articles are shown below.

DTG8

Articles mentioning DTG

8 articles · page 1 of 1

OC36 Durability of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir-based single tablet regimens in a large cohort of experienced PWH: the BIC-LASTING study

sextrans · abstract · 2026-06-05 · 8 matching annotations

90.0%

dolutegravir bictegravir emtricitabine DTG tenofovir alafenamide abacavir 3TC rilpivirine DTG-STR lamivudine

…ctegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) vs. dolutegravir (DTG)-based single tablet regimens (STR) on treatment failure-r…

P164 Switching to DTG/3TC or FTC/TAF/BIC in people living with HIV already on a stable TAF including regimen does not change weight and lipid profile

sextrans · abstract · 2026-06-05 · 8 matching annotations

88.3%

DTG emtricitabine TAF lamivudine dolutegravir

… HCV-coinfection, no significant differences were found between DTG and TAF group as regards weight, BMI and lipid profile (see tab…

P20 B/F/TAF vs DTG: similar durability, different reasons for discontinuation. results of a real-life study

sextrans · abstract · 2026-05-20 · 6 matching annotations

88.7%

Dolutegravir bictegravir darunavir abacavir atazanavir rilpivirine 3TC lamivudine emtricitabine DTG+1 more

…ain characteristics of 2359 PWH enrolled in the Bictegravir and Dolutegravir SCOLTA cohortsAbstract P20 Table 2Reasons for 568 discontinuati…

Lingering sex and age disparities in dolutegravir uptake among adults with HIV: a multicountry observational cohort study

bmjgh · abstract · 2026-03-13 · 6 matching annotations

89.3%

DTG dolutegravir HIV WHO DTG-for-All ART

…oduction Since July 2019, the WHO has recommended dolutegravir (DTG)-based regimens as preferred first-line antiretroviral therapy …

OC68 Clinical outcomes in PWH switching from oral combinations with dolutegravir (DTG) + lamivudine (3TC) or rilpivirine (RPV) to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): data from the Italian ICONA foundation cohort (OPTIMIZE-BIC analysis)

sextrans · abstract · 2026-06-05 · 2 matching annotations

77.1%

B/F/TAF DTG-based DTG PWH HIV-RNA

…d from DTG+3TC or DTG+RPV (single- or multi-tablet regimens) to B/F/TAF, between Jul-2019 and Apr-2025, regardless of HIV-RNA at switch…

Research news in clinical context

sextrans · abstract · 2026-05-19 · 2 matching annotations

85.8%

zidovudine DTG 5 mg DTG dolutegravir HIV-negative

…birth, accounting for transplacental DTG exposure and alongside zidovudine postnatal prophylaxis. DTG plasma concentrations at 6–10 days s…

4CPS-106 Cost-effectiveness analysis of HIV antiretroviral therapy regimens: real-world evidence from the Italian Mosaico study

ejhpharm · abstract · 2026-03-18 · 2 matching annotations

82.8%

DTG/3TC TAF DTG FTC HIV MOSAICO PWH PLWH

… a trend towards economic optimisation.Conclusion and Relevance DTG/3TC represents the most cost-effective option among analysed regime…

Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial

bmjopen · abstract · 2026-02-05 · 2 matching annotations

92.7%

DTG DOlutegravir 3TC TDF emtricitabine lamivudine doravirine FTC DTG-based DOR+3 more

…te (TDF) (300 mg daily) plus lamivudine (3TC) (300 mg daily) or DTG (50 mg daily) in combination with TDF (300 mg once daily) plus …

Browse drugs

DTG

Articles mentioning DTG